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Abstract
HDL metabolism and its relationship to atherosclerosis is a
complex topic, though notable advances have been made.
First, HDL clearly has an anti-atherogenic action. Second,
this action is due to some fraction/s containing apoA-I but
not apoA-II. Third, some of the molecular mechanisms in-
volved in two key anti-atherogenic functions of HDL have
been defined: reverse cholesterol transport and prevention
of LDL oxidative modification. These advances may permit
the development of effective strategies, complementing
those already available, for treating and preventing athero-
thrombotic cardiovascular diseases.
Resum
L’estudi del metabolisme de les HDL (lipoproteïnes de den-
sitat alta) i la seva relació amb l’arteriosclerosi és un tema
complex, en el qual, recentment, s’han fet avenços impor-
tants. Primer, s’ha demostrat que les HDL tenen una acció
antiaterogènica. Segon, s’ha establert que aquesta acció és
deguda a fraccions que tenen apoA-I però no apoA-II. Ter-
cer, s’han definit alguns mecanismes clau en l’acció antiate-
rogènica de les HDL: transport invers de colesterol i preven-
ció de la modificació oxidativa de les LDL (lipoproteïnes de
densitat baixa). És previsible que aquests avenços perme-
tran el desenvolupament d’estratègies efectives, que com-
plementaran les existents per al tractament i la prevenció de
les malalties cardiovasculars aterotrombòtiques.
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1. Introduction
High-density lipoproteins (HDL) form one of the main
lipoprotein families present in plasma. It is a lipoprotein fam-
ily of very heterogeneous particle size, apolipoprotein com-
position and density (which varies between 1.063 g/ml and
1.21 g/ml). Cholesterol transported by HDL is a protective
factor against atherosclerosis, whereas the cholesterol pre-
sent in low-density lipoproteins (LDL) constitutes a risk fac-
tor. It is therefore generally considered positive to have a
high concentration of HDL cholesterol in plasma together
with a low level of LDL cholesterol. These concepts have
their basis in several clinical and epidemiological studies
that have demonstrated an inverse relationship between the
concentration of plasma HDL cholesterol and the risk of suf-
fering atherosclerosis, while this relationship is direct in the
case of LDL cholesterol [1, 2]. Nevertheless, the relation-
ship between HDL and atherosclerosis is complex and has
exceptions. For example, patients with very infrequent ge-
netic alterations which cause almost total deficiencies of
HDL do not appear to run any greater risk of atherothrom-
botic cardiovascular disease than control subjects [3]. This
feature has recently been reproduced in animals in which
genes of vital HDL proteins were specifically knocked out
[4]. As an explanation for these discrepancies, it has been
postulated that the relationship between the concentration
of HDL cholesterol and atherothrombotic cardiovascular
disease might only be secondary to alterations in the me-
tabolism of triglyceride-rich lipoproteins [3]. However, the
antiatherogenic capacity of increased HDL plasma concen-
tration has recently been demonstrated in animal models [5-
10]. Another explanation for the lack of increased cardio-
vascular risk of many HDL deficiencies is that these usually
present with a concomitant considerable reduction in LDL
cholesterol [11].
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The functions of HDL are also controversial, especially
those which are probably determinant in their antiathero-
genic action. This review summarises the present vision of
the relationship between HDL and atherosclerosis, particu-
larly concerning its molecular bases.
2. Structural characteristics and HDL classification
The name «HDL» implies the use of a criterion of density to
classify lipoprotein families. The various classifications and
terminologies (which depend on the method used) for HDL
are shown in Table 1. They are particularly relevant given
that many of the studies on HDL attempt to assign the an-
tiatherogenic action of HDL to specific particle subpopula-
tions. Using this same criterion of density as a classification,
two predominant HDL types, HDL2 (density between 1.063
g/ml and 1.125 g/ml) and HDL3 (density between 1.125 g/ml
and 1.210 g/ml), can be distinguished. Although it is a very
minor fraction in humans, HDL1 or apolipoprotein E (apo E)-
enriched HDL is also found in other animals. This fraction is
less dense than HDL2, although its limits are not well de-
fined. Its high apoE content aids its characterisation. Anoth-
er form of classification, of growing importance, classifies
HDL particles according to their apolipoprotein content.
ApoA-I is quantitatively the most abundant protein in HDL,
followed by apoA-II. This gives rise to the frequently used
concepts of HDL with apoA-I and without apoA-II, HDL with
apoA-I and with apoA-II, and HDL with apoA-II and without
apoA-I [12]. This classification does not include the content
of HDL apolipoproteins: C-I, C-II, C-III, A-IV, E, D, J and H.
Thus, even within each of these types of particles, there is
marked apolipoprotein heterogeneity. For a summary of the
characteristics of HDL apolipoproteins, see Table 2. Another
classification is based on the electrophoretic mobility in
agarose gels of HDL populations, according to their electric
charge. These are classified as !, pre-" and #. HDL can be
separated for size by non-denaturing gel electrophoresis in
polyacrylamide gradient gels. The populations obtained
with this method, which are similar to those obtained by ul-
tracentrifugation, are called (from smaller to greater size)
HDL3c (7.62mm), HDL3b, HDL3a, HDL2a and HDL2b
(10.57 mm) [13].
3. ApoA-I
3.1. Structure and properties
ApoA-I is the principal protein component (68%) of HDL. It
is also present in small quantities in chylomicrons, but not
in lipoproteins which contain apoB-100. Thus, this apoli-
poprotein is only found in physiological conditions in HDL
during fasting, when clinical analyses are usually made.
ApoA-I is made up of 243 amino acids and has an approxi-
mate molecular weight of 28 kD [14]. It is synthesised in liv-
er and intestine, as a product of a gene found in the q23 re-
gion of chromosome 11, near the apo C-III/apoA-IV/insulin
gene cluster [15]. The apoA-I gene belongs to a family of
genes which codify small and soluble apolipoproteins (A-I,
A-II, A-IV, E, C-I, C-II and C-III), characterised by a struc-
ture of 4 exons and 3 introns. Exon 4 codifies many repeat-
ed series of 11 or 22 amino acids that generate zones of
the !-helical properties called amphipathic helices (Figure
1). These, on interacting with phospholipids, are formed by
two opposing sides, one hydrophobic and the other hy-
drophilic. The hydrophobic side is in contact with the
aliphatic chains of fatty acids, while the hydrophilic part is
in contact with the aqueous medium, interacting with the
most polar region of phospholipids and with free choles-
terol [16].
Table 1. HDL classification depending on the methodology used for
their isolation.
Ultracentrifugation HDL2 (density between 1.063-1.125 g/ml)
HDL3 (density between 1.126-1.210 g/ml)
Electrophoresis in HDL2b (particle diameter, 10.6 nm)
polyacrylamide HDL2a (particle diameter, 9.2 nm)
gels HDL3a (particle diameter, 8.4 nm)
HDL3b (particle diameter, 8 nm)
HDL3c (particle diameter, 7.6 nm)
Electrophoresis in !-HDL
agarose gels pre"-HDL
#-HDL
Immunoaffinity HDL with apoA-I and without apoA-II
chromatography HDL with apoA-I and apoA-II
HDL without apoA-I and apoA-II
Table 2. Characteristics of HDL apolipoproteins.
Name Molecular Plasma Function
weight concentration
(kD) (mg/dl)
apoA-I 28 130 structural, LCAT cofactor,
cholesterol efflux, SRB-I
ligand
apoA-II 17 40 ?
apoA-IV 46 12 LCAT cofactor
apoC-I 6.5 12 favouring triglyceride
exchange
apoC-II 8.8 12 LPL cofactor
apoC-III 8.7 12 LPL inhibitor
apoD 29 5 transport of lipophilic
substances?
apoE 34 2 Ligand for receptors,
cholesterol efflux
apoJ 70 ? clearance of apoptotic
residues?
apoH 43 20 inhibition of coagulation?
apoK-45 45 4 inhibition LDL oxidative
modification,
Hydrolysis of
homocysteine thiolactone
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After its synthesis, apoA-I is called pre-pro-apoA-I, which
is a precursor form of high molecular weight. Upon passing
to cytoplasm, it is converted into pro-apoA-I. Subsequently,
in the bloodstream and lymph, it is converted into the mature
protein through the action of an as yet not well characterized
plasmatic converter enzyme [17].
ApoA-I has an important structural function in HDL, since
its deficiency is associated with HDL deficiency. Various
models of apoA-I structure in nascent discoidal HDL have
been proposed [18]. In one of the two more credible models,
the helices are parallel to the plane of the lipid disc and, in
the other, the helices are anti-parallel [18]. The physico-
chemical characteristics of the two models make the parallel
structure seem more likely, at least in a model of association
of up to two molecules of apoA-I in a single lipid disc [18].
The spheroidal particles of HDL contain from 2 to 4 mole-
cules of apoA-I whose structure is probably similar to that of
discoidal HDL [18]. ApoA-I plays a fundamental role in the
first steps of the efflux of cholesterol from the cells (see sec-
tion 8.1.1 for more details) and is the cofactor of the enzyme
lecithin:cholesterol acyltransferase (LCAT) (19).
3.2. Mutations of the apoA-I gene
The hypothesis that HDL deficiencies caused by apoA-I
deficits increase the risk of atherosclerosis accounts for the
effort made to characterise mutations of the apoA-I gene
and establish the genotype-phenotype associations of the
different mutations found. Although, at first, some patients
with deletions and inversions of the apoA-I/apoC-III/apoA-IV
cluster seemed to present the expected increase in coro-
nary atherosclerosis, after the description of more than 20
mutations of apoA-I (although not all affect the concentration
of HDL cholesterol) this hypothesis has not been confirmed
[for a thorough review, see references 3 and 20]. Neither pa-
tients with almost total HDL deficiency nor their family mem-
bers present a greater risk of atherosclerosis than the con-
trol population [11]. Three of these apoA-I mutations which
greatly diminish HDL cholesterol but are not associated with
a greater risk of atherosclerosis are Arg173Cys (apoA-I Mi-
lano), Pro165Arg, and Gly26Arg (apoA-I Iowa) [3]. Surpris-
ingly, apoA-I Milano seems to be an important protective
factor against atherosclerotic cardiovascular disease. In
support of this, epidemiological as well as experimental data
demonstrate that its administration inhibits fattening of the
carotid intima in hypercholesterolaemic rabbits and in apoE
knock-out mice, which are models of accelerated and 
massive atherosclerosis, and that it inhibits thrombosis 
[21-23]. Several apoA-I mutations have been found in pa-
tients with amyloidosis (for example, Gly26Arg, Leu60Arg
and deletion of residues 60-71 of the protein which were
substituted by valine and threonine), although the nature of
this association is unclear [24]. Another interesting case is
that of the mutations of apoA-I which cause dominant auto-
somal inherited hypoalphalipoproteinaemia. These are
apoA-I Milano (Arg173Cys), apoA-I Seattle (deletion of
amino acids 146-160), apoA-I Paris (Arg151Cys), apoA-I
Finland (Leu159Arg) and apoA-I Oslo (Arg160Leu) [25]. We
recently studied various generations of one family from the
Mediterranean island of Mallorca, who have a history of
dominantly inherited hypoalphalipoproteinaemia due to a
heterozygous deletion of amino acids 165-175 of the apoA-I
(apoA-I Mallorca) (Martín-Campos et al., J. Lipid Res. 2002;
Figure 1. A structural model of apolipoprotein A-I, common to other soluble apolipoproteins, in which the amphyphatic helices are separated
by prolines.
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43:115-123). This family does not show any increased car-
diovascular risk, even though the proband was studied be-
cause of coronary atherosclerosis. In all apoA-I Mallorca
carriers there is failure to activate LCAT, suggesting that the
presence of a molecule of mutated apoA-I could alter the ca-
pacity of cholesterol esterification in HDL [25] and cause an
increase in HDL, as has been described in inherited forms of
primary LCAT deficiency.
3.3. ApoA-I transgenic animals
The first generated human apoA-I transgenic mice ex-
pressed the transgene only in liver, despite the fact that the
microinjected construction contained 5.5 Kb of the 5’ ex-
treme and 4 Kb of the 3’ extreme. Hence, it was concluded
that the genetic elements, which control apoA-I expression
in the intestine, differ from the liver elements and are outside
the above-mentioned genomic region [26]. A later study
demonstrated that the site in which intestinal expression of
apoA-I is induced is found in the DNA situated between 0.3
Kb and 1.4 Kb of the 5’ extreme of the gene of the adjacent
apoC-III [27]. In fact, it is suspected that this region also
controls intestinal expression of the other two components of
the cluster, the apoC-III and apoA-IV genes.
Human apoA-I transgenic mice have higher HDL choles-
terol than controls, which correlates with the concentration of
human apoA-I. These transgenic mice are deficient in
mouse apoA-I through an undetermined post-transcriptional
mechanism. Overexpression of human apoA-I in the mouse
reproduces the size heterogeneity characteristic of human
HDL as well as the increase in concentration of apoA-I and
HDL cholesterol produced in response to fat-rich diets [28-
30]. This contrasts with characteristics of control mice in
which HDL size is homogeneous and in which a fat-rich diet
decreases the plasma concentration of apoA-I and HDL
cholesterol. Thus, differences between the structure of hu-
man and mouse apoA-I determine the size profile of the HDL
particles as well as their plasma concentration in response
to a fat-rich diet. The generation of an animal model in which
HDL increases after a fat-rich diet is relevant because it per-
mits detailed study of the molecular mechanisms governing
the plasma concentration of apoA-I and HDL cholesterol in
pro-atherogenic conditions [31].
The development of transgenic mice, rats and rabbits for
the apoA-I gene has permitted study of their effect on ather-
osclerosis susceptibility. The conclusion of the different
studies appears clear: apoA-I overexpression prevents ath-
erosclerosis in mice and rabbits fed a fat-rich diet [7, 32].
Overexpression of human apoA-I also prevents accelerated
atherosclerosis after angioplasty in rats, apparently by re-
duction in the proliferation of muscle cells [33]. Additionally,
overexpression of apoA-I in transgenic mice prevents ather-
osclerosis in genetically-modified mice which suffer massive
atherosclerosis. This is the case of apoE-deficient mice [9,
10] and apo(a) transgenic mice [8]. In conclusion, these
studies demonstrate that apoA-I overexpression leads to an
increase in HDL cholesterol and is able to prevent athero-
sclerosis. This concept coincides with epidemiological data
which found an inverse relationship between HDL choles-
terol and the risk of coronary atherosclerosis.
Genetically-modified mice by inactivation (knock-out) of
the apoA-I gene have also been produced [4, 34]. These an-
imals are deficient in HDL, thereby demonstrating that apoA-
I is critical for HDL structure [4]. The absence of apoA-I
causes LCAT functional deficiency, which also illustrates the
necessity of apoA-I as cofactor of this enzyme in vivo, de-
spite the fact that apoA-I is not necessary for maintaining the
concentration of LCAT in plasma [35]. LCAT deficiency
alone is a sufficient factor to cause HDL deficiency. Mice
without apoA-I do not develop more atherosclerosis than
controls when fed a regular chow diet [36]. However, there is
an increase in atherosclerosis susceptibility in apoA-I-defi-
cient mice overexpressing human apoB-100 [37]. Thus,
these data support the finding in human studies that the in-
crease in apoA-I and HDL prevents atherosclerosis; howev-
er, their deficiency does not necessarily favour atherosclero-
sis development unless other risk factors exist.
Finally, the study of mice genetically modified to lack
apoA-I has enabled the important and specific function of
apoA-I in the transport of HDL cholesterol to steroidogenic
tissues to be established. In these animals, but not in mice
deficient in apoA-II with a similar deficiency of HDL choles-
terol, a decrease in cholesterol ester content is observed in
steroidogenic tissues [34].
Among the possible actions of HDL invoked to explain
their anti-atherogenic action, reverse transport of cholesterol
and prevention of the oxidative modification of LDL stand
out. Hence, the greater resistance of apoA-I transgenic mice
to atherosclerosis may be due to an increase in these ac-
tions. In fact, it has been demonstrated that isolated HDL of
apoA-I transgenic mice prevent the oxidative modification of
LDL more than HDL of control mice do [38]. In contrast, the
serum of apoA-I transgenic mice did not induce a greater ef-
flux of cholesterol in Fu5AH rat hepatoma cells [39], which is
the first step in reverse cholesterol transport.
4. ApoA-II
4.1. Structure and properties
The apoA-II gene is found in the q21-23 region of chromo-
some 1 [40]. Synthesis takes place in the liver although small
quantities of RNA are also found in the small intestine [41].
The most abundant form of apoA-II in human plasma is a ho-
modimer of 77 amino acids linked by a disulphide linkage
between the cysteines in position 6 of each monomer [42].
Other less abundant molecular forms are the apoAII-apoE
and apoA-II-apoD heterodimers and the monomer [43, 44].
ApoA-II has a high percentage of !-helix (62%) [45], with
closer affinity than that of apoA-I for lipid monolayers. This
explains why an excess of apoA-II can displace apoA-I from
the HDL surface [46].
Plasma concentration of apoA-II in normolipaemic indi-
viduals is, on average, 33-35 mg/dl [47], which represents
approximately 20% of HDL protein and constitutes the sec-
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ond most abundant HDL apolipoprotein. Kinetic studies
have demonstrated that, unlike apoA-I, the concentration of
apoA-II in plasma is mainly regulated by the synthesis rate
rather than by its catabolism [47].
ApoA-II function is poorly defined and its study has pro-
duced contradictory results: different studies in vitro have
concluded that apoA-II either activates or inhibits the action
of hepatic lipase (HL) [48] and CETP [49, 50]. In addition,
opposing effects have been described as to whether HDL
containing apoA-I and apoA-II favour or antagonise the ef-
flux of cellular cholesterol [51, 52]. However, there is greater
consensus that apoA-II is not, unlike apoA-I, a cofactor of
LCAT [46, 53-56].
4.2 Mutations of the apoA-II gene
The only known case of a human apoA-II mutation is in a
Japanese family with an apoA-II deficiency due to a muta-
tion in the first nucleotide of the third intron of the apoA-II
gene [57]. Despite the absence of apoA-II in two members
of this family, these did not present lipoprotein changes or
show signs or symptoms of atherosclerosis, suggesting that
at least in humans the function/s of apoA-II can be replaced
by other proteins. In fact, some animal species, such as
dog, pig, cow, chicken and rabbit, have undetectable apoA-
II in their plasma. In clear contrast, mice genetically modified
to lack apoA-II develop HDL deficiency [58]. Thus, mouse
but not human apoA-II plays a critical role in HDL.
4.3 ApoA-II transgenic animals
Overexpression of apoA-II in transgenic mice has been
achieved using both the human gene and the mouse gene.
The results obtained in the two cases clearly differ. Thus, it is
likely that the structural differences between the two proteins
have significant functional repercussions. Overexpression
of human apoA-II causes the appearance of smaller HDL
particles than in the plasma of control mice [56, 59]. Further-
more, mouse apoA-II and apoA-I deficiency exists in the
lines of transgenic mice with greater concentration of human
apoA-II (70 mg/dl). As a consequence of the apoA-I deficit,
a functional deficiency in LCAT was also observed [55, 56,
60], even though LCAT concentration was normal [56, 60].
This is due to a lack of reactivity towards LCAT of apoA-II-
rich HDL particles, which results in a marked decline in !-
HDL particles concomitant with a mild accumulation of free
cholesterol in the cornea, which resembles a condition in hu-
mans due to partial LCAT deficiency, known as Fish Eye Dis-
ease [55, 61].
It has been clearly shown that human apoA-II overexpres-
sion has a pro-atherogenic effect since it increases the ath-
erosclerosis susceptibility of transgenic mice [61]. It also in-
creases atherosclerosis in apoE-deficient mice [62] and,
though less consistently, in double human apoA-II/simian
CETP transgenic mice [63]. Moreover, joint overexpression
of human apoA-II and apoA-I genes results in a partial loss
of the protection to atherosclerosis conferred by apoA-I
overexpression. This does not appear to be due to changes
in the lipid composition of HDL, since no significant differ-
ences are observed between the HDL of apoA-I transgenic
mice and of apoA-I/apoA-II transgenic mice [64].
Mice overexpressing apoA-II (mouse apoA-II transgenic
mice) are characterised by increased concentrations of HDL
cholesterol and larger HDL particle size than in controls [65].
As in human apoA-II transgenic mice, they show greater
susceptibility to atherosclerosis, though this is more evident
in a regular chow diet than in an atherogenic diet [66]. These
characteristics coincide with those observed in one con-
genic strain selected by high expression of apoA-II [67,68].
One of the fundamental differences between human and
mouse apoA-II is that the latter does not have cysteines in its
structure and, thus, is found exclusively in a monomeric
form. However, overexpression of human apoA-II gene mu-
tated to not contain cysteines does not reproduce the
lipoprotein phenotype of mouse apoA-II transgenic mice,
suggesting that other structural differences between the two
molecules are partially responsible for the different effects of
their expression in mice [69].
Hence, apoA-I-rich HDL protects against atherosclerosis,
but apoA-II-rich HDL does not. This could be due to various
mechanisms: first, disruption of reverse cholesterol trans-
port associated with a diminution of the efflux of cellular cho-
lesterol and a marked impairment in LCAT activity [55, 56,
60, 61, and 70]; and second, increased susceptibility to HDL
oxidation [71] and/or loss of HDL protection against LDL ox-
idative modification (Ribas et al., unpublished observa-
tions). These alterations may have greater repercussions
because of the increased plasma concentration of apoB-
containing lipoproteins present in these animals due to in-
creased VLDL production [72, 61-63, 73]. Since the overpro-
duction of VLDL is the basic characteristic of familial
combined hyperlipidaemia and that the gene of the human
apoA-II is situated near (but outside) a «major» gene caus-
ing familial combined hyperlipidaemia [74], the function of
apoA-II may be to block the synthesis or function of the
product of the mentioned gene or the metabolic pathway in
which this, as yet unknown, protein functions. This seems
plausible, as various studies have demonstrated a relation-
ship between the apoA-II plasma concentration and apoA-II
locus and the apoA-II plasma concentration and the metab-
olism of free fatty acids and triglycerides [31, 75-77; see ref-
erence 62 for extensive discussion on this point].
5. Other HDL apolipoproteins
5.1. apoA-IV
ApoA-IV is a 46-kD glycoprotein which is mainly associated
with HDL and the non-lipoprotein fraction of plasma during
fasting, or with chylomicrons during the postprandial period
[78]. The apoA-IV gene is mainly expressed in the intestine.
There is a particularly interesting polymorphism in this gene,
which determines the change of histidine to glutamine in po-
sition 360 (apoA-IV-2 allele) and is present in approximately
8% of the Western population. The most frequent form (histi-
dine 360) is called the apoA-IV-1 allele. Individuals with an
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apoA-IV-2 allele have higher concentrations of triglycerides
and lower levels of HDL cholesterol in plasma than homozy-
gotes for the apoA-IV-1 allele. In addition, they are more re-
sistant to change in lipid concentrations in response to diets
with a varied content of cholesterol and saturated fatty acids
[78].
Diverse functions have been suggested for apoA-IV,
some of which have already been proposed as the function
of other apolipoproteins. ApoA-IV may be a regulator of the
action of lipoprotein lipase on chylomicrons [79]. Patients
with a hereditary deficiency of apoA-I-C-III-A-IV present vita-
min E deficiency, which does not occur in patients with an in-
herited deficiency of apoA-I-C-III. This observation has sug-
gested a role of apoA-IV in the absorption of liposoluble
vitamins [80, 81]. Another role attributed to this apolipopro-
tein was as a mediator of satiety in the central nervous sys-
tem. Studies carried out in apoA-IV transgenic mice found
no variation in the absorption of liposoluble vitamins or in the
dietary habits of these animals [82]. A possible explanation
is that a limited concentration of apoA-IV is sufficient for car-
rying out these functions and that variations above this level
have null effect. Alternatively, and given that transgenic
mice overexpress apoA-IV throughout their lives, it is possi-
ble that compensating mechanisms have been developed.
Analysis of knock-out mice for this gene is likely to be more
informative in this respect. Lastly, apoA-IV has a stabilising
effect on LCAT and activates the efflux of cholesterol in cell
cultures, for which it can be an important part of the reverse
cholesterol transport. In this context, it is noteworthy that
apoA-IV is mainly found in particles without apoA-I and
which contain LCAT and CETP [83]. However, apoA-IV not
associated with lipoproteins is widely present in interstitial
tissue, which is consistent with its potential action in reverse
transport of cholesterol.
Human-apoA-IV transgenic mice fed a fat-rich diet pre-
sent fewer lesions of atherosclerosis than control mice.
Moreover, apoA-IV overexpression reduces atherosclerosis
in apoE-deficient mice [84]. At least in this model, the an-
tiatherogenic action of apoA-IV is independent of the HDL
cholesterol concentration.
5.2. apoD
This apolipoprotein belongs to the superfamily of lipocalins
and is found in plasma, associated mainly with HDL [44]. It is
a 169-amino acid protein whose function is largely unknown.
It has been postulated that it could bind ligands such as
progestagens or arachidonic acid, although the physiologi-
cal significance of this function and its relationship with HDL
metabolism are currently unknown [85, 86].
5.3. apo E
Although this is an interesting and well-studied apolipopro-
tein, most of its characteristics are unrelated to a function in
HDL. Of special interest for HDL metabolism is the existence
of pre-" migrating HDL which contain apoE and seem able
to induce the early steps of reverse transport of cholesterol
from cell membranes to plasma [87]. However, since these
particles are only present in individuals who have at least
one apoE3 allele and not in individuals homozygous for the
apoE4 or apoE2 alleles [88], apoE polymorphism could be
an important determinant of reverse transport of cholesterol.
In addition, the presence of apoE in HDL is related to the ef-
fectiveness of the transfer of HDL cholesterol esters to the
SR-BI receptor [89].
5.4. apoJ (also called clusterine or sulphated glycoprotein 2)
This is a 427-amino acid glycoprotein of approximately 70
kD molecular weight post-transcriptionally fragmented be-
tween residues 205 and 206, which results in two units of
apoJ (one containing amino acids 1-205 and the other con-
taining amino acids 206-427). Both units remain bound
through disulphide linkages [90, 91]. ApoJ is synthesised in
a great variety of tissues. It is found in plasma, mainly in HDL
particles which do not contain any other apolipoprotein, al-
though at least some of these particles do also contain
paraoxonase (for more information on this enzyme, see sec-
tion 6.8). In some studies, a clear increase has been demon-
strated in the apoJ/paraoxonase ratio in mice susceptible to
atherosclerosis, and also in patients with coronary artery dis-
ease [92]. ApoJ has been demonstrated to bind to the gly-
coprotein 330 receptor, as do other ligands such as lipopro-
tein lipase or apoE [93]. Glycoprotein 330 receptor is
structurally similar to the LDL-related receptor (LRP), but is
mainly expressed in the liver. Given that apoJ increases in
damaged tissues and exerts inhibitory activity on the C5b-
C9 complex, it has been proposed that apoJ may function
with glycoprotein 330 receptor to clear lipid or apoptotic
residues.
5.5. apoH
This protein, also known as "2-glycoprotein I, is associated
with, as well as HDL, chylomicrons, VLDL and the non-lipopro-
tein fraction of plasma. Although its function in lipoprotein me-
tabolism remains unknown, it has been postulated that it has
an inhibitory function in coagulation [94].
5.6. apoK-45
Little was known on this protein until its sequence was found
to be identical to that of paraoxonase [95]. Its structure and
function will be analysed in detail in section 6.8.
5.7. Serum amyloid-A proteins (SAA)
Serum amyloid-A proteins are a family of highly homologous
molecules that meet the physico-chemical criteria for being
considered apolipoproteins, and which form part of HDL.
This family can be divided into two groups [96]. The first
group includes amyloid proteins which increase spectacu-
larly during the acute phase reaction that follows severe dis-
eases or traumas. It had been suggested that these proteins
displace apoA-I from the surface of HDL and can become,
in the stated pathological circumstances, the main protein
component of HDL. Two genes which codify for SAA1 and
SAA2 exist, although there are allelic variations which are re-
sponsible for the existence of different isoforms in each
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gene. The second group consists of a group of proteins
(SAA4 in humans and SAA5 in mouse) which constitute 1%
to 2% of HDL proteins in physiological situations.
Until recently it was believed that the functional LCAT de-
ficiency associated with the acute phase reaction was sec-
ondary to the decreased level of apoA-I in HDL. However,
overexpression of amyloid-A protein (to levels comparable
to those in humans with an acute phase reaction) in apoA-I
transgenic mice does not cause a reduction in HDL choles-
terol or apoA-I in the absence of the mentioned reaction
[97], thereby suggesting that inflammatory mediators are re-
quired to obtain this response. In contrast, overexpression of
phospholipase A2 in transgenic mice, also in the absence of
acute phase reaction, did increase HDL catabolism, sus-
ceptibility to oxidative modification of LDL and atherosclero-
sis [98-100]. Thus, the function of amyloid proteins in the
metabolism and function of HDL remains to be determined.
6. Enzymes, transporters and receptor proteins
involved in HDL metabolism
Different proteins that do not form part of HDL structure,
such as enzymes, lipid transport proteins and receptors, are
extraordinarily significant in HDL metabolism, as inherited
deficiencies of these proteins clearly demonstrate. As well
as the already classic lipoprotein lipase (LPL) and hepatic li-
pase (HL), a new member of this family of enzymes, en-
dothelial lipase, has recently been characterised. Interest-
ing new findings have also been reported in the field of HDL
receptors.
6.1. Lipoprotein lipase (LPL)
The general characteristics of this protein are more usually
analysed in relation to the metabolism of triglyceride-rich
particles than that of HDL. However, different studies exist
relating, albeit indirectly, LPL activity and HDL cholesterol
plasma concentration [101, 102]. Also, it is known that per-
sons with an inherited LPL deficiency (familial chylomicron-
aemia) have greatly reduced HDL cholesterol [103]. This is
probably because LPL acts on chylomicrons and VLDL by
changing their cortex/core ratio and these lipoproteins tend
to recover their primitive relationship by breaking off pieces
of cortex that will float in the density range of HDL2 [104]. A
complementary explanation to explain the correlation be-
tween LPL activity and HDL cholesterol is that the former de-
termines the duration of postprandial lipaemia. Further, the
longer the postprandial lipaemia, the greater HDL triglyc-
erides (through increased PTEC activity) is and, thus, in-
creased HL activity and increased HDL catabolism (see
sections 6.2 and 7).
6.2. Hepatic lipase (LH)
This enzyme is found on the surface of endothelial liver cells,
from where it can be released by heparin perfusion. Its ac-
tion is to hydrolyse phospholipids and triglycerides [105,
106], particularly on IDL and HDL. In the latter, it causes
conversion of large (HDL2) into smaller particles (HDL3).
This is due to hydrolysis of HDL triglycerides and induces
dissociation of apoA-I from HDL [107]. This is likely to be a
major source of very small lipid-poor HDL particles whose
only apolipoprotein is apoA-I and which have electrophoret-
ic migration of pre-"3-HDL [108]. These particles, a minor
quantitative fraction of HDL –probably corresponding in part
to the above-mentioned very-high-density lipoproteins
(VHDL, density between 1.21 g/ml and 1.24 g/ml)–, are likely
to be quantitatively the main receptors of cellular cholesterol
in tests in which the rapid component of cholesterol efflux is
measured.
The development of HL transgenic and knock-out animals
(mice and rabbits) has confirmed and extended our knowl-
edge of this enzyme. Rabbits and mice overexpressing HL
present decreased levels of HDL cholesterol and reduced
HDL particle size [109-111], while HL-deficient animals pre-
sent large buoyant HDL particles enriched in phospholipids
and apoE. These findings corroborate the hypothesis that HL
metabolises these types of particles [112]. Double HL/apoA-
II-deficient mice do not present the same degree of HDL cho-
lesterol deficiency as apoA-II knock-out mice, which suggests
that apoA-II inhibits the effects of HL on HDL metabolism in
mice [113]. However, these results should be extrapolated to
humans with great caution, since humans with apoA-II defi-
ciency do not present HDL deficiency. This discrepancy
could be because a good part of mouse HL binds to plasma
HDL, whereas this is not the case with human HL which binds
to the surface of hepatocytes. All this suggests species-spe-
cific differences in the regulation of HL.
Recent studies suggest that allelic variation in HL could
account for 25% of the total variability in HDL cholesterol, at
least in Western populations [114].
6.3. Endothelial lipase
This is a lipase which has only recently been cloned and
analysed. It is synthesised by endothelial cells in vitro and is
expressed in vivo by diverse tissues and organs, including
liver, placenta, lung and kidney, but not skeletal muscle.
This enzyme has a phospholipase action, mainly on HDL.
Overexpression of this gene leads to a decrease in HDL
cholesterol and apoA-I, thereby suggesting a functional role
in HDL metabolism [115].
6.4. Lecithin: cholesterol acyltransferase (LCAT)
This is a 416-amino acid enzyme which catalyses the hydrol-
ysis and transfer of a fatty acid from phosphatidylcholine to a
cholesterol molecule (in position 3-"-OH), producing as a re-
sult cholesterol ester and lisolecithin [116]. The active site of
this enzyme includes serine 181 [117-119]. This process of
cholesterol ester formation occurs especially in HDL, given
that apoA-I and apoA-IV are cofactors of the reaction [35, 55,
56]. The apoA-I region responsible for LCAT activation is sit-
uated in the region between amino acids 143 and 186 (re-
peats 6 and 7) and requires a specific conformation which is
obtained during its association with lipids [120]. Part of the
cholesterol esterified by LCAT stems from cell membranes,
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but the main source of free cholesterol is LDL. Esterification
of cholesterol is a very important step in HDL maturation and
reverse cholesterol transport [121, 122].
Human LCAT has been overexpressed in three different
animal models. In rabbits and monkeys, where CETP is pre-
sent and active in plasma, LCAT overexpression increases
plasma apoA-I and HDL cholesterol, but decreases LDL
cholesterol owing to an increase in LDL catabolism via the
LDL receptor. It also causes a reduction in atherosclerotic
lesions induced by an atherogenic diet [123-125]. Overex-
pression of human LCAT in transgenic mice also resulted in
hyperalphalipoproteinaemia [55, 126, 127], but there was no
decrease in apoB-containing lipoproteins concomitant with
an unexpected increase in atherosclerosis susceptibility
[128]. This could be explained by the accumulation of non-
functional large HDL that may be pro-atherogenic. The in-
creased susceptibility to atherosclerosis in these mice is
corrected by CETP expression [129], suggesting that the
different profiles observed in several transgenic models are
due to differences in CETP activity in the animals used for
LCAT transgenesis.
A further important finding from the study of these geneti-
cally-modified animals is that LCAT can bind to HDL parti-
cles enriched in apoA-II. However, LCAT presents little activ-
ity towards HDL containing little or no apoA-I [35, 55-56].
In contrast, LCAT-deficient mice presented a large de-
crease in HDL cholesterol, apoA-I, apoA-II, and an increase
in plasma triglycerides and accumulation of small nascent
HDL [130-132]. Additionally, paraoxonase and platelet acetyl-
hydrolase factor activities were lower in this model, although
liver mRNA levels were comparable to those of control mice
[133]. An increase in expression of the adrenal SR-BI mes-
senger was also observed in LCAT-deficient mice [132].
Considerable experience of the consequences of LCAT
deficiency has been obtained from study of patients with in-
herited deficiency of this enzyme. Inherited LCAT deficien-
cies may be either complete or partial (also known as Fish
Eye Disease) [134, 135]. While plasma LCAT mass and/or
activity is non-existent or very low in LCAT deficiency, there
is a measurable amount of activity towards artificial and en-
dogenous substrates in Fish Eye Disease. In both cases,
however, there is a major decrease in HDL cholesterol con-
centration which may approach zero. However, the clinical
and pathological differences between both entities are very
noticeable. While the only clinical signs in partial LCAT defi-
ciency are corneal opacities, which may seriously impair vi-
sion after the fifth or sixth decades of life, complete LCAT
deficiency also causes anaemia, as the result of distortion of
red cell membranes, and renal failure [135]. The mutations
that cause LCAT deficiencies are distributed throughout the
LCAT gene in both Fish Eye Disease and total LCAT defi-
ciency: in both cases mutations affect both alleles [134].
Recent evidence indicates that the renal lesion in patients
with total LCAT deficiency may be due to greater susceptibil-
ity to oxidative modification of phospholipids [136]. This sup-
ports the potential viability of prevention (i.e. with anti-oxidant
vitamins) in patients who have been diagnosed in a pre-
symptomatic period [137]. In fact, LCAT appears to help pro-
tect against oxidation of lipoproteins since it hydrolyses short
polar chains of phosphatidylcholine formed during oxidation
[138] and prevents lipid oxidation in vitro [139]. There is also
evidence that lipid oxidation inhibits LCAT activity (140).
6.5. Cholesteryl ester transfer protein of cholesterol esters
(CETP or LTP-1)
CETP (or Lipid-transport protein 1, LPT-1) is a 74-kD protein
whose gene is located in chromosome 16q13. This protein is
secreted into plasma from different tissues and is mainly
linked to HDL in circulation, from where it promotes the ex-
change and redistribution between the different lipoprotein
classes of cholesteryl esters, triglycerides and, in lesser
quantity, phospholipids [141]. Given that a major part of
cholesteryl esters are in HDL and most triglycerides are
found in chylomicrons and VLDL, CETP activity results in a
net transfer of cholesteryl esters from HDL to triglyceride-
rich lipoproteins, whereas the opposite is true for triglyc-
erides. This process, in the case of increased plasma VLDL,
may be dependent on CETP, given that VLDL catabolism is
faster than that of LDL and HDL. CETP action reduces the
content of HDL cholesterol and increases that of apoB-con-
taining lipoproteins. However, given that the catabolic rate of
LDL and HDL is slow and similar for both lipoproteins, the re-
sult is usually independent of CETP concentration [141].
Since its identification, the role of CETP in lipoprotein me-
tabolism and atherosclerosis susceptibility has been the sub-
ject of discussion. CETP can be anti-atherogenic by partici-
pating in cholesterol reverse transport. However, CETP action
increases VLDL/LDL cholesterol and HDL triglyceride (an HL
substrate) and could therefore be pro-atherogenic [141].
Studies performed on CETP transgenic mice have not
clarified matters. Simian CETP expression in control mice
and in human apoA-II transgenic mice [63, 142] and that of
human CETP in apoE-deficient mice [143] increased athero-
sclerosis susceptibility. In contrast, CETP expression in oth-
er hypertriglyceridaemic mice, like those overexpressors of
apoC-III, induced a reduction in atherosclerosis susceptibil-
ity [144]. Also, CETP expression prevented atherosclerosis
in human LCAT transgenic mice [128]. One interpretation of
these results could be that CETP prevents atherosclerosis
when it improves reverse cholesterol transport (i.e. in the
case of double LCAT/CETP transgenic mice).
However, at least two studies have demonstrated the anti-
atherogenic potential of inhibiting CETP in rabbit, an animal
with high activity of this protein in its plasma [145, 146].
Inherited CETP deficiencies have been described in hu-
mans and appear to be relatively frequent in the Japanese
population (up to 5% of the population is heterozygote for
this deficiency) [147]. In the Honolulu Heart Study, an ex-
cess of coronary disease was confirmed in subjects with
CETP deficiency. When CETP deficiency was associated
with an HDL-cholesterol concentration between 1.06 and
1.55 mmol/L, coronary risk was higher than in subjects with
similar HDL cholesterol levels but without CETP deficiency
[148]. However, there was no increase in coronary risk for
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those deficient in CETP when HDL cholesterol was above
1.55 mmol/L [147]. In this event, the benefits of high HDL
cholesterol overcome the effects of impaired reverse choles-
terol transport due to CETP deficiency.
It has recently been demonstrated that CETP synthesis is
induced by the interaction of the LXR (liver X receptor) with
the CETP gene promoter [149]. The fact that this transcrip-
tion factor also regulates the promoter of 7!-hydroxylase
cholesterol, the key enzyme in the synthesis of biliary acids
from the cholesterol delivered to the liver by HDL, could be
considered evidence of the molecular coordination of the
different steps of reverse cholesterol transport [148].
6.6. Phospholipid transporter protein (PLTP and/or LTP-2)
This is a protein of 476 amino acids with a molecular weight
of 54.7 kD, to which N-glycosylation gives an apparent mole-
cular weight of 75 kD. Prior to its characterisation, it was re-
ferred to as a converter activity because of its ability to in-
duce changes in HDL size [150]. PLTP secretion depends
on the segment comprised between residues 35 and 50,
and also on intracellular folding of the protein which is in-
duced by a disulphide linkage between cysteines 129 and
168 [151, 152]. Its association with HDL is due to the binding
of PLTP to apoA-I, near residues 27 to 48 of this apolipopro-
tein [153]. PLTP is synthesised in ovary, thymus and placen-
ta and to a lesser degree in the majority of other organs. Its
function consists of transferring phospholipids from some
HDL particles to others, thereby causing displacement of
apoA-I from the HDL surface and, thus, generation of small-
er HDL particles (pre-"1 HDL) [154, 155]. The resulting HDL
particles tend to undergo fusion, which explains why PTLP
also generates larger HDL particles [56, 157].
As studies performed in cholesterol-loaded fibroblasts
show, PLTP may play an important role in cellular cholesterol
and phospoholipid efflux by increasing binding of HDL to
cells. This efflux is HDL-specific and is not seen if only albu-
min or purified apoA-I are found in the medium, or in the
case of fibroblasts of patients with Tangier disease [158].
PLTP can additionally transfer free cholesterol, !-tocopherol
and lipopolysaccharide, which suggests that it may also be
involved in anti-microbial defence [159]. Its capacity to
transfer !-tocopherol from HDL and complexes of !-toco-
pherol-albumin towards LDL and endothelium may indicate
a function in the prevention of LDL oxidative modification
and an additional entry pathway of !-tocopherol to endothe-
lial cells [160].
Another interesting property of this protein is its proteolyt-
ic serine-esterase activity, which is able to cut the carboxy
terminal extreme of apoA-I (28.2 kD), leaving a fragment of
22.9kD. This proteolytic activity acts on both free apoA-I and
apoA-I/phospholipid complex of density greater than 1.250
g/ml, showing an induction phase (or lag phase) of 8-10
hours at 37ºC after which proteolysis occurs in a time-de-
pendent manner [161]. The physiological significance of this
activity is unknown, but it has been suggested that it may af-
fect HDL metabolism by generating an apoA-I compartment
with increased catabolism.
The generation of PLTP-deficient mice has provided in
vivo evidence of the importance of this protein in HDL me-
tabolism. These mice show a decrease in plasma phospho-
lipids, cholesterol and apoA-I HDL when they are fed a regu-
lar chow diet. However, when these animals are fed a
fat-rich diet, they present increased plasma phospholipids,
free and esterified cholesterol associated with VLDL and
LDL without changes in apoB content [162]. In another
study, these animals showed accelerated HDL catabolism
as well as accumulation of lamellar apoA-IV-rich lipoproteins
[163]. These results support a role of PLTP activity in the
transfer of phospholipids and free cholesterol from triglyc-
eride-rich lipoproteins to form nascent HDL.
Human PLTP transgenic mice only showed phenotypic
effects after breeding with human apoA-I transgenic mice. In
this case, increased phospholipids and HDL cholesterol
were found in plasma due to an increase in pre-" HDL [164].
In another study in which PLTP was overexpressed in mice
(between 2.5 and 4.5 times more than in controls), their plas-
ma showed a 2-3-fold increase in pre-" HDL and was more
efficient than control plasma in preventing cholesterol accu-
mulation in macrophages [165].
PLTP overexpression by adenovirus in control or apoA-I
transgenic mice caused, nevertheless, a marked decrease
in HDL cholesterol and the appearance of some HDL of
greater size than in control mice [166]. Studies of alcoholic
patients, before and after giving up alcohol, showed that
while CETP activity tends to increase small HDL particle for-
mation, the predominant action of PLTP is the opposite
[167].
6.7. Cholesterol efflux regulatory protein (CERP)
Several groups [168-171] have recently cloned and se-
quenced this protein. Based on theoretical predictions, it is a
protein with 12 transmembrane domains and two intracellu-
lar ATP binding sites, which could provide energy for the
transfer of ligands. In this model, the protein presents two
halves, with six transmembrane helices, each bound by a
large hydrophobic segment containing a regulatory region
[172] (Figure 2).
This protein was identified and characterised during the
study of the defective gene in Tangier disease. Those affect-
ed by this rare inherited disease have extremely low HDL
levels and show an accumulation of cholesterol esters in en-
dothelial reticulum cells, which is the origin of some of the
clinical characteristics of the disease, such as he-
patomegaly, spleen enlargement, orange-coloured tonsils
[173] and a higher risk of atherosclerosis. Tangier disease is
caused by defects in the ATP-binding cassette transporter-1
gene (ABC-1 and/or ABCA-1, according to the Human Gene
Nomenclature Committee) which codifies for CERP. Further-
more, mutations of this gene have been found in patients
with familial HDL deficiency, suggesting that Tangier dis-
ease and familial HDL deficiency are allelic manifestations of
mutations of the same gene [168]. Marked impairment of
CERP function (i.e. mutations in homozygosis or compound
heterozygosis) may lead to the most severe form (accumula-
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tion of cholesterol in tissues and HDL deficiency which char-
acterise Tangier disease), while less impairment (i.e. in het-
erozygotes) may cause HDL deficiency but without the clini-
cal manifestations of massive cholesterol accumulation in
tissues (familial HDL deficiency).
CERP defects cause a decreased efflux of cellular phos-
pholipids and cholesterol towards HDL, thus severely im-
pairing reverse lipid transport and HDL formation. CERP-de-
ficient mice show a severe HDL deficiency and other
alterations consistent with the phenotype of patients affect-
ed by Tangier disease. In both, the transport of lipids from
the Golgi to the plasma membrane is defective [174, 175].
CERP is found in the plasma membrane, which is consistent
with its possible function as transporter of lipids to HDL [176].
CERP expression is regulated. It is absent in proliferating cells,
but is induced by quiescence, especially in cholesterol-
loaded macrophages [176]. CERP presents a consensus re-
gion of kinase proteins dependent on cAMP, suggesting that
phosphorylation of the protein may have functional effects.
Consistent with this, cAMP has been described as increasing
both CERP mRNA and protein expression on the cell surface
[176]. Furthermore, cAMP analogues induce apolipoprotein-
mediated lipid efflux. It has been demonstrated that apoA-I
binds to a membrane protein of molecular weight identical to
CERP [177] and that IL-1" stimulates the apoA-I-dependent
efflux of cholesterol and phospholipids, which suggests that at
least some cytokines can modulate CERP [178].
CERP probably transfers free cholesterol and phospho-
lipids between the internal and the external parts of the plas-
ma membrane, where they are captured by apoA-I for HDL
formation. Although it is not yet known whether these are
their true ligands or whether other cell proteins are involved
[179], their importance in cell lipid efflux towards HDL is evi-
dent.
Other results suggest that CERP participates in the
phagocytosis of apoptotic cells and secretion of IL 1-" by
macrophages [180].
6.8. Paraoxonase
This enzyme belongs to the group of type A esterases. It is
able to hydrolyse diverse organophosphates, which ex-
plains the interest of toxicologists in it. Paraoxonase is a pro-
tein of approximately 45 kD, whose gene is situated in the
long arm of chromosome 7. The paraoxonase gene (also
called PON1) is part of a family which has at least three relat-
ed genes that share a high degree of homology and which
are grouped together (the others are called PON2 and
PON3) in the same chromosome region, thereby suggesting
gene duplication [181]. Paraoxonase is mainly synthesized
and secreted by the liver and is associated with HDL in plas-
ma, especially in particles containing apoA-I and apoJ
[182]. A special characteristic of this protein is the retention
of the hydrophobic signal in the N-terminal end, which is re-
sponsible for its union with HDL through phospholipid bind-
Figure 2. A model of the product of the ATP-binding cassette protein-1 (ABC-1), known as the cholesterol efflux regulatory protein (CERP),
which is defective in Tangier disease and familial HDL deficiency.
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ing [183]. Given that it is unlikely that the function of paraox-
onase is to metabolise synthetic substances, the question is:
what is its function? Paraoxonase protects against inflamma-
tion in cells of the arterial wall, probably by destroying bio-
logically active lipids from oxidised lipoproteins. A possible
mechanism could be the hydrolysis of lipid peroxides in oxi-
dised lipoproteins, especially hydroperoxide phospholipids
[184]. On the other hand, a calcium-dependent HDL en-
zyme, homocysteine:thiolactone hydrolase –which is known
to protect against one of the potential toxic effects of hyper-
homocysteinaemia, the accumulation of homocysteine thio-
lactone– has recently been purified and found to be identical
to paraoxonase [185].
Various polymorphisms of the paraoxonase gene have
been described. One is associated with a different activity of
the enzyme using paraoxon as a substrate. While isoform A
(low activity) has Gln in position 192, isoform B (high activity)
has Arg in the same position [186, 187]. However, some
studies found an increase in genotypes AB and BB in pa-
tients with coronary artery disease [188, 189], though others
found no differences in the genotype distribution of patients
and controls [190, 191]. The explanation could be the
greater protective effect of paraoxonase A (low activity
against paraoxon) than of B (high activity against paraoxon)
on lipoprotein oxidation [192]. Thus, the active centre re-
sponsible for paraoxonase/arylesterase activity is not the
same as the centre responsible for protection against oxida-
tion. Protective activity against oxidation seems to involve
the free cysteine of paraoxonase (Cys 284) and does not re-
quire the N terminal domain, which is responsible for HDL
binding [192].
Another polymorphism affects amino acid 55 of paraox-
onase which can be a methionine or a leucine. In one study,
homozygosity for leucine in position 55 was found to be an
independent risk factor for cardiovascular disease [193],
though this has not been confirmed in other studies [194].
Polymorphisms which influence the plasmatic concentra-
tion of the enzyme have also been described in the promoter
of the paraoxonase gene. These polymorphisms are situat-
ed in positions -907, -824 and -107, the last of which may be
important for gene expression [195]. By affecting the plasma
concentration of paraoxonase, these polymorphisms could
contribute to the study of the protective capacity of paraox-
onase against atherothrombotic cardiovascular disease.
The development of paraoxonase-deficient mice has re-
vealed a clear relationship between paraoxonase expres-
sion and the formation of atherosclerotic lesions. Besides
being more susceptible to organophosphates, as expected,
paraoxonase-deficient mice were more susceptible to ather-
osclerosis than control mice. Both LDL and HDL isolated
from these mice were more susceptible to oxidation than
LDL and HDL of control mice [196]. These findings, in-
creased susceptibility to oxidation and to atherosclerosis,
have been replicated in double apoE/paraoxonase-deficient
mice [197].
Non-genetic factors may affect paraoxonase concentra-
tion and activity. In the strain of mice susceptible to athero-
sclerosis C57BL/6J, a decrease in paraoxonase in plasma
was observed after eight weeks of atherogenic diet. This ef-
fect was not observed in the strain of mice genetically resis-
tant to atherosclerosis C3H/Hej [198]. In apoE-deficient
mice, ageing increases lipid peroxidation, which is concomi-
tant with decreased paraoxonase activity [199], while the
addition of antioxidants to their diet preserves paraoxonase
activity [200]. A decrease in paraoxonase activity in the
plasma of human volunteers is also observed four hours af-
ter a meal rich in fried oils [201]. These observations sug-
gest that dietary and environmental factors also modulate
the activity of paraoxonase in plasma.
During the acute phase response, a change in HDL pro-
tein composition occurs, which is associated with de-
creased paraoxonase and platelet activating factor acetyl-
hydrolase activities [202]. Acute phase response induced
by lipopopolysaccharide injection in hamsters causes a de-
crease in both plasma activity and paraoxonase mRNA. This
is mediated by the pro-inflammatory cytokines TNF! and IL-
1 [203]. It is thus possible that acute repetitive or chronic in-
flammation could be pro-atherogenic.
Finally, it is relevant that paraoxonase 3 (PON3) has been
cloned and expressed, for this shows that, in rabbits at least,
PON3 protects against oxidation more powerfully than
paraoxonase 1 [204].
6.9. Platelet activating factor acetylhydrolase (PAF-AH)
This calcium-independent serine esterase is associated with
LDL (especially the dense LDL of 1.050<d<1.063 g/ml) and
with HDL, 70% and 30%, respectively. The nature of PAF-AH
binding to LDL has been studied by directed mutagenesis,
which has shown the importance of residues 205, 115 and
116 of PAF-AH and the C-terminal extreme of apoB-100 of
LDL in this binding. This occurs in human LDL, while in mice
there is no association of PAF-AH with LDL and the greater
part of this enzyme is associated with HDL [205].
PAF-AH acts by hydrolysing the sn-2 ester bond of the
platelet activating factor (1-alkyl-2-acetyl-sn-glycero-3-
phosphocholine, PAF) and liberating acetate. This enzyme
also hydrolyses the minimally-oxidised peroxide fatty acids
of LDL phospholipids, action which prevents endothelial
cells from segregating inflammatory factors promoting
monocyte binding [206]. Oxidised phospholipids could be
transferred from LDL to HDL, where they could be inactivat-
ed by hydrolysis. PAF-AH action in HDL prevents the peroxi-
dation of LDL; and this is not prevented if a serine esterase
inhibitor is used [207]. Apparently, PAF-AH and paraox-
onase act jointly in lipoprotein oxidation protection, as sug-
gested by the fact that PAF-AH is not effective in preventing
LDL oxidation in paraoxonase-deficient mice [208].
LDL oxidation causes PAF-AH activity to decrease, prob-
ably due to the formation of a non-competitive inhibitor
[209].
6.10. HDL receptors
Though various authors have identified proteins that bind
HDL in membranes of fibroblasts, hepatocytes, adipocytes
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and macrophages, the physiological function of many of
these is still unknown. Therefore, in this review we will focus
on two receptors, one of which (cubilin) is able to internalise
HDL particles as well as apoA-I, whereas the other (named
CLA-1 or SR-B1, depending on the authors) captures HDL
cholesteryl esters without internalisation of the lipoprotein
particle.
Cubilin is expressed in the intestinal epithelium, kidney
and placenta, and mediates catabolism of small HDL and
lipid-poor apoA-I. Previously, cubilin had been described
as an intestinal receptor of the complex vitamin B12-intrin-
sic factor [210, 211]. Thus, it is likely to be a «multi-ligand»
receptor. Cubilin is a protein of 400 kD. As it does not con-
tain any transmembranous segment in its structure, it
needs the co-expression of another protein, megalin, which
is a member of the LDL receptor family and does contain a
transmembrane segment. This suggests that it acts as a
co-receptor with cubilin. Both cubilin and megalin are ex-
pressed in the proximal renal tubule. In the kidney, their
function could be the reabsorption and degradation of
small HDL and lipid-poor apoA-I from the glomerular fil-
trate. In the intestine, cubilin is important for the absorp-
tion of vitamin B12, and in the placenta it could be the
transport pathway of cholesterol from the mother to the foe-
tus [212].
SR-BI (scavenger receptor BI) [213] or CLA-1 [214] is a
protein of 57 kD whose theoretical structure contains two cy-
toplasmatic domains, a large extracellular region and two
transmembrane domains [215]. SR-BI is expressed in liver,
ovaries and adrenal glands [214], which led researchers to
hypothesise on its possible function, especially as these tis-
sues are known to capture HDL cholesteryl esters. The re-
ceptor seems to be located in caveolae, at least in some cell
types [216], while in other studies an association was found
in other domains of the plasma membrane where caveolae
had not been identified [217]. An isoform of this receptor,
named SR-BII, has a different C-terminal domain due to al-
ternative splicing. This isoform is less efficient in capturing
HDL cholesteryl esters, although its function is largely un-
known [218].
The selective transfer of HDL cholesteryl esters to cells
appears to need direct binding of the HDL particle to SR-
BI, probably by recognition of amphipathic helices charac-
teristic of soluble apolipoprotein [219] such as apoA-I,
apoA-II, apoC, although SR-BI can also bind anionic phos-
pholipids of vesicles that do not contain proteins [220].
Once an HDL particle is bound to the SR-BI surface, it 
has been postulated that a hydrophobic canal would be
formed and cholesteryl esters would cross the cell plasma
membrane following a favourable gradient [221]. The role
of SR-BI in this transfer seems to be more important than
the simple binding of HDL near the plasma membrane,
since a related receptor, CD36, also binds HDL but is inca-
pable of mediating such a net transfer of cholesteryl esters.
It has been suggested that the extracellular domain of SR-
BI is responsible for generating such a hydrophobic canal
[222].
SR-BI also promotes cell efflux of free cholesterol. It has
been suggested that this phenomenon is not only due to
HDL binding but is also dependent on the change of mem-
brane lipid domains which facilitate a bi-directional flow of
free cholesterol [223].
SR-BI activity in the selective recruitment of cholesteryl
esters may be important in the liver during the final steps of
cholesterol reverse transport. Mice overexpressing liver SR-
BI present very rapid clearance of HDL particles as well as
an increase in biliary cholesterol [224]. Furthermore, a muta-
tion in the SR-BI promoter of mice, which reduces the ex-
pression of this receptor by half, results in increased plasma
concentration of HDL cholesteryl esters as well as increased
HDL particle size [225]. These effects are more dramatic in
mice completely deficient in SR-BI. Moreover, these mice
present a decrease in adrenal cholesterol [226] and female
infertility. This suggests that the SR-BI-mediated pathway is
important for the production of steroid hormones by adrenal
glands.
Other murine models presenting an HDL deficiency, such
as those of mice deficient in LCAT [132], apoA-I and HL
[227], also present a concomitant increase in SR-BI receptor
expression in adrenal glands, apparently of a compensatory
nature since the increase is parallel to a drop in cholesteryl
esters in this tissue.
Oestrogens and dietary cholesterol regulate SR-BI ex-
pression in liver, while regulation of the expression in adren-
al glands is mediated by the hypothalamic-pituitary-adrenal
axis, mainly through ACTH [228].
The relationship between this receptor and atherosclero-
sis has also been studied by inducing genetic modifications
in mice. Double apoE/SR-BI-deficient mice present much
more rapid atherosclerosis than apoE-deficient mice [229]
and, consistently, LDL receptor-deficient mice overexpress-
ing SR-BI present fewer atherosclerotic lesions than LDL re-
ceptor-deficient mice [230]. It has been suggested that part
of the SRB-I protection against atherosclerosis could be due
to its ability to bind apoB-containing lipoproteins, in addition
to its action on reverse cholesterol transport. It is noteworthy
that SR-BI mediates the selective transfer of HDL-oxidised
cholesteryl esters to the liver and may be responsible for
their rapid clearance, which could contribute to their an-
tiatherogenic effect [231].
There are several polymorphisms of the human SR-BI lo-
cus which are associated with variations in lipid and anthro-
pometric parameters [232], which suggests that this recep-
tor helps regulate body weight.
Recently, the increased plasma HDL-cholesterol concen-
tration present in Ob/Ob mice (deficient in leptin) has been
shown to be due to a drop in HDL catabolism (binding, asso-
ciation, degradation and re-secretion) in hepatocytes. This
implies decreased recruitment of HDL cholesteryl esters,
even though SR-BI expression is not altered [233]. The mol-
ecular mechanisms involved are unclear; thus, whether
there are one or more HDL receptors other than SR-BI and
megalin/cubilin, and whether leptin regulates the function of
one or more HDL receptors, remain to be clarified.
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7. Metabolism of HDL: determinants of HDL
cholesterol plasma concentration
HDL synthesis occurs at different levels: hepatic, intestinal
and circulating plasma. ApoA-I and apoA-II are synthesised
in the liver and seem to be secreted as lipid-poor particles or
even as free apolipoproteins. These apolipoproteins capture
phospholipids and cholesterol from cells or bind lipids origi-
nated by lipolysis-induced remodelling of triglyceride-rich
lipoproteins. These discoidal lipoprotein particles are later
converted into mature spherical HDL by LCAT activity [83,
234]. The intestine synthesises and secretes HDL particles
with apoA-I with or without apoA-IV, but without apoA-II (the
principal synthesis site of this apolipoprotein is the liver). Fi-
nally, a part of HDL is synthesised during the catabolism of
triglyceride-rich lipoproteins.
Various clinical studies have demonstrated that post-he-
parin LPL activity correlates with the concentration of HDL2
cholesterol [102]. However, the mechanism by which this is
produced is unknown, since the surface material liberated
from triglyceride-rich lipoproteins is probably denser than
HDL2. One possibility is that this surface material binds
apoA-I and phospholipids and matures by the action of
LCAT reaching the density characteristic of HDL2. Another
possibility is that this surface material undergoes fusion with
pre-existing HDL particles.
Now that the structure and composition of HDL, as well as
the main related enzymes, lipid transport proteins and recep-
tors involved in their metabolism, have been reviewed, it is now
possible to review the most contrasted aspects of HDL metab-
olism, with special emphasis on the processes that modulate
the interconversion of different subtypes of HDL (Figure 3).
Figure 3. Summary of HDL metabolism with particular reference to reverse cholesterol transport.
156 Francesc González Sastre, Vicent Ribas and Francisco Blanco-Vaca
HDL catabolism is the main determinant of HDL plasma
concentration in the population. The main determinant of
HDL catabolism appears to be lipid composition and parti-
cle size, which are highly dependent on their interaction with
lipolytic enzymes and transfer lipid proteins [235]. Both
these parameters, lipid composition and particle size, are
closely related. In most pathophysiogical circumstances, a
very close correlation exists between plasma concentrations
of apoA-I and HDL cholesterol. Despite this, it is clear that
the destination of part of the lipid and protein components of
a given HDL particle differs from that of the lipoprotein parti-
cle [236, 237]. This is due to a rapid substitution of some
lipid and protein components of HDL. This occurs through,
first, the phospholipase and the triglyceride-lipase actions of
HL; second, the action of lipid transfer proteins (LTP-1 or
CETP and LTP-2), which transfer cholesteryl esters, triglyc-
erides and phospholipids (in the case of CETP) or only phos-
pholipids (in the case of LTP-2) to other lipoprotein particles;
and lastly, the specific transfer of cholesteryl esters to cells
in a process mediated by specific receptors (SR-BI) which
recognise HDL and lipid-poor apoA-I in liver, adrenal gland
and ovaries.
The actions of these enzymes and lipid transport proteins
on HDL induce the dissociation of part of the apoA-I mole-
cules contained in a given HDL particle. Lipid-poor or lipid-
free apoA-I may form HDL particles by inducing reverse
cholesterol transport or, alternatively, be filtered in the kid-
ney and catabolised at tubular level by the megalin/cubilin
complex [211, 212, 237]. The renal catabolism of free apoA-
I explains why its clearance from plasma is higher than for
the whole HDL particle.
Factors which tend to increase or decrease HDL concen-
tration are shown in Table 3. As previously mentioned, the
most frequent mechanism involved in decreased plasma
HDL cholesterol is increased HDL catabolism. This is the
case in hypertriglyceridaemia, where the increase in HDL
catabolism seems to result from the increase in either the
number of triglyceride-rich particles, its lipid content, or
both. Both situations will produce HDL triglyceride enrich-
ment by CETP. This will increase HL action on HDL, de-
crease HDL particle size and increase apoA-I dissociation
from the HDL surface [102, 238]. There is an inverse rela-
tionship between HDL particle size and their clearance
[235], with the small HDL particles being more rapidly
catabolised.
One of the genetic determinants of HDL cholesterol con-
centration in the general population has been situated in the
gene whose defect causes Gaucher’s disease. Mutations of
this gene in heterozygosis could cause 19.5% of the genetic
variability of HDL cholesterol, at least in the Spanish popula-
tion [239]. Whether this gene affects HDL synthesis or ca-
tabolism is, at present, unknown.
The same mechanisms that explain decreased HDL cho-
lesterol in individuals with hypertriglyceridaemia, i.e. de-
creased LPL activity and/or increased HL and CETP activi-
ties, may explain decreased HDL cholesterol in individuals
without hypertriglyceridaemia. In some cases, changes in
the concentration and/or activity of these proteins have an
important genetic basis. Decrease in HDL cholesterol due to
a decrease in the LPL/HL ratio appears to be more strongly
associated with coronary disease than CETP increases
[240].
It is noteworthy that not all causes of increased HDL cho-
lesterol shown in Table 3 can be associated with greater pro-
tection against atherosclerosis, and the reverse is also true
for the causes of decreased HDL cholesterol. For example,
the increase in saturated fat intake increases HDL choles-
terol, which occurs in a pro-atherogenic context. In addition,
some cases of increased HDL cholesterol (hyperal-
phalipoproteinaemia) due to inherited HL or CETP deficien-
cies could be associated with a greater risk of atherosclero-
sis, although this is in part in the former case due to the
increased concentration of remnant lipoproteins [241, 242].
Some inherited HDL deficiencies do not appear to be associ-
ated with greater atherogenic risk. Thus, although a clear epi-
demiological relationship exists between levels of HDL cho-
lesterol and atherogenic risk, exceptions to this rule do exist.
8. HDL functions of potential anti-atherogenicity
The effect of expressing or deleting several genes whose ef-
fects are related to HDL metabolism and atherosclerosis
susceptibility is shown in Table 4.
Numerous functions which could have physiological sig-
nificance have been ascribed to HDL. Some of these are list-
ed in Table 5. However, at present there are no data indicat-
ing the relative contribution of these functions to the total
anti-atherogenic capacity of HDL. Two of the most anti-
atherogenic functions are examined in detail below.
8.1 Reverse cholesterol transport
This term indicates the process by which cholesterol origi-
nating from peripheral cells is captured by HDL to be deliv-
ered to the liver, from where it will be partly eliminated
through the biliar pathway. This hepatic clearance of choles-
terol is, in humans, carried out mainly through VLDL, IDL and
LDL. The process by which cholesteryl esters are transport-
ed from HDL to apoB-containing lipoproteins (chylomicrons,
VLDL, IDL and LDL) is mediated by CETP. Three processes
Table 3. Factors influencing the plasma concentration of HDL cho-
lesterol
Raises HDL cholesterol Lowers HDL cholesterol
Sex: female Sex: male
Exercise Sedentary habits
Alcohol Abdominal obesity
Saturated fat-rich diets Saturated low-fat diets
CETP deficiency Polyunsaturated fat-rich diets
Hepatic lipase deficiency Hypertriglyceridaemia
Oestrogens Progestagens, androgens
Niacin Probucol
Fibrates Smoking
Phenytoin
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are involved in the reverse cholesterol transport: cholesterol
efflux from cells to plasma, cholesterol esterification and
destination of preformed cholesteryl esters (see Figure 3).
8.1.1. Cholesterol efflux
Two theories exist on cellular cholesterol efflux to HDL. The
first is that this efflux is a diffusive, slow, receptor-indepen-
dent process. HDL particles which capture cholesterol do
not have any special characteristic (HDL with apoA-I and
without apoA-II and HDL with apoA-I and apoA-II are equal-
ly capable of inducing this cholesterol efflux) [155, 243] (Fi-
gure 3). A second theory proposes that cholesterol efflux is
receptor-dependent and that HDL with apoA-I and without
apoA-II are more efficient than HDL with apoA-I and apoA-II
[155, 243]. Some authors have even suggested that HDL
particles with apoA-I and apoA-II not only are not capable of
promoting cholesterol efflux, but also block the process by
competing for binding to the receptor [244, 245].
The current belief is that both processes can co-exist, and
that in some cell types, cholesterol efflux occurs using both
systems, while in others one of the efflux systems is predomi-
nant. However, there has been progress in defining a mech-
anism of rapid and specific cholesterol transport to a minor
fraction of HDL, the pre-"HDL. This type of particle only con-
tains apoA-I, and accounts for only 5% of total HDL. Its ability
to recruit cholesterol is lost, to a great extent, if cultured cells
are previously treated with proteases, indicating specificity
though not demonstrating a specific interaction mediated by
receptors [243]. It is supposed that the type of interaction be-
tween the pre-" HDL and a hypothetical receptor induces
cholesterol translocation from the cytoplasm to the cell mem-
brane and could correspond to CERP and, perhaps, to other
members of the ABC protein group [176, 179].
Three types of pre-" HDL exist. The pre-" HDL1s are the
smallest particles and those which first receive cell choles-
terol. After a few minutes, the cholesterol passes to pre-"
HDL2 and to pre-" HDL3, which are particles increasingly
Table 4. Modification of HDL-related genes in experimental animals: effects on HDL cholesterol and atherosclerosis susceptibility.
Abbreviation not used in the text: H, human
Animal Species Modification HDLc level Atherosclerosis Reference
Mouse Apo AI KO Decreased Unchanged 36
Mouse ApoA-I KO/H apoB transgenic Increased Decreased 37
Mouse H ApoA-I transgenic Increased Decreased 7
Mouse Double H ApoA-I/Apo(a) transgenic Unchanged Decreased 8
Mouse H ApoA-I transgenic/apoE KO Increased Decreased 10
Rabbit H apo AI transgenic Increased Decreased 32
Mouse Apo AII KO Decreased ND 58
Mouse Apo AII transgenic Increased Increased 66
Mouse H apo AII transgenic Decreased Increased 60
Mouse H ApoA-II transgenic/apoE KO Decreased Increased 62
Mouse Double H ApoA-II/ simian CETP transgenic Decreased Increased 63
Mouse H Apo AIV transgenic Unchanged Decreased 84
Mouse H hepatic lipase transgenic Decreased Decreased 109
Mouse Hepatic Lipase KO Increased ND 112
Mouse Hepatic Lipase/Apo AII-double KO Decreased ND 113
Mouse H Endothelial Lipase adenovirus expression Decreased ND 115
Rabbit H-LCAT transgenic Increased Decreased 123
Mouse H LCAT transgenic Increased Increased 128
Mouse Double H LCAT/ CETP transgenic Increased Decreased 129
Mouse LCAT KO Decreased ND 132
Mouse Simian CETP transgenic Decreased Increased 142
Mouse Double H CETP /Apo AI transgenic Decreased Increased 144
Mouse Triple H CETP / Apo AI / Apo CIII transgenic Decreased Decreased 144
Mouse PLTP KO Decreased ND 163
Mouse H PLTP transgenic Increased Decreased 165
Mouse Double H PLTP/ Apo AI transgenic Increased ND 164
Mouse ABCA-1 KO Decreased Increased 175
Mouse paraoxonase KO and double paraoxonase/apoE KO Unchanged Increased 196, 197
Mouse SR-BI KO Increased ND 226
Mouse Double SR-BI / apoE KO Increased Increased 229
Table 5 . Potential anti-atherogenic HDL functions.
* See references 264-270 for details
Reverse cholesterol transport
Prevention of LDL oxidative modification
Inhibition of LDL aggregation (*)
Suppression of the inhibition of the endothelial relaxing factor (*)
Prostacycline production and stability (*)
Inhibition of macrophage migration (*)
Inhibition of the expression of adhesion molecules by
endothelial cells (*)
Increase in protein S and C activities (*)
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greater in size. Authors differ as to whether the major part of
cholesterol is mainly esterified in pre-" HDL and transferred
to !-HDL and LDL, or whether a greater part is transferred
unesterified to !-HDL first and later to LDL [54, 243, 246].
According to this latter theory, free cholesterol is re-trans-
ferred to !-HDL (mainly HDL3), where it is esterified by
LCAT. In short, this esterification process is a key step for
maintaining the gradient of transfer from LDL to HDL. In sup-
port of the latter hypothesis, the principal source of non-es-
terified cholesterol for HDL is LDL and not cells [243].
8.1.2. Cholesterol esterification
Plasma cholesterol esterification is catalysed by LCAT. The
importance of LCAT action for the two cholesterol efflux sys-
tems postulated varies. Complete LCAT deficiency does not
have the same impact on all tissues. Furthermore, there is
experimental evidence indicating that LCAT activity is not
necessary to produce the rapid and specific component of
cholesterol efflux, which is directed, in the first place, to HDL
particles of pre-" mobility. However, LCAT activity is neces-
sary for the slowest non-specific component of cholesterol
efflux, which is directed to HDL particles in a concentration-
dependent fashion [247]. In this regard, it has been hypoth-
esised that the reverse of LCAT deficiency (i.e. a disease
which principally affects the cell lines which depend funda-
mentally on reverse rapid and specific transport of choles-
terol) is Tangier disease [247, 141]. This disease is charac-
terised by accumulations of cholesteryl esters, especially in
cells derived from the reticulum-endothelial system [142].
8.1.3 Destination of cholesteryl esters formed in HDL
Destination of cholesteryl esters formed in HDL is varied.
These esters can be: i) captured by tissues together with the
whole HDL particle, especially in the liver and kidney; ii)
captured in a specific way from HDL after their binding to the
SR-BI receptor (this process does not imply capture of the
HDL particle by the cell) in the liver, gonads and adrenal
glands; and iii) transferred by CETP to apoB-containing
lipoproteins which are later captured by the cells via a re-
ceptor-mediated mechanism (LDL receptor, VLDL receptor,
LRP, gg330, etc).
HDL metabolism, with special reference to the reverse
cholesterol transport process, is summarised in Figure 3.
8.2. Prevention of oxidative modification of LDL
Oxidised modification of HDL inhibits reverse cholesterol
transport and blocks LCAT activity [248-250]. Thus, oxida-
tive modification of HDL could inhibit one of the anti-athero-
genic functions of HDL such as reverse cholesterol trans-
port. However, current research focuses on the ability of
HDL to inhibit LDL oxidative modification, a phenomenon
that appears to be vital in the origin of atherosclerosis [251,
252]. The mechanism of this inhibition seems to be, at least
in part, enzymatic. By means of poorly defined interactions
between LDL and HDL, HDL enzymes –such as the coaction
of paraoxonase and PAF-AH– convert oxidised fatty acids
with pro-atherogenic properties into others which have no
biological activity [184, 207] (see Figure 4 for a view of this
hypothetical anti-atherogenic mechanism). This function
Figure 4. Hypothetical mechanisms by which paraoxonase (PON) and platelet activated factor acetylhydrolase (PAF-AH) protect against ath-
erosclerosis.
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may be vital for explaining the anti-atherogenic role of hu-
man apoA-I which, when expressed in transgenic mice, rais-
es the activity of both paraoxonase and PAF-AH [253]. Other
non-enzymatic properties directly mediated by apoA-I (but
not by apoA-II or albumin) also block the steps that lead to
LDL oxidative modification [254, 255]. HDL protection of
LDL oxidative modification is altered in patients with coro-
nary artery disease [254, 255].
At least some of these interactions between LDL and HDL
may be mediated by the lipid transport proteins (CETP and
LTP-2), proteins with an unknown function since the biologi-
cal function of the exchange of lipids between lipoproteic
particles is not evident [256]. It has been shown that HDL
are the principal lipoprotein group in which cholesteryl es-
ters with hydroperoxides accumulate [257]. At the same
time, it is known that oxidised cholesteryl esters in HDL are
cleared eight times more rapidly than HDL cholesteryl esters
by cell cultures of hepatomas [258]. The SR-BI receptor
seems to be involved in this clearance, which is not surpris-
ing if one considers that it belongs to the family of scavenger
receptors [178, 231].
9. Therapeutic potential of increasing plasma HDL
in atherosclerosis treatment and prevention.
Experiments with transgenic animals demonstrate that HDL
containing apoA-I without apoA-II have greater anti-athero-
genic force than HDL with both apoA-I and apoA-II [7, 64].
Moreover, overexpression of apoA-I in these animals is ca-
pable of protecting against atherosclerosis caused by vari-
ous induced genetic defects (apoE deficiency or high levels
of Lp(a), changes that supposedly increase atherosclerosis)
[7, 8, 9, 10, 32]. Hence, one possible way to treat or prevent
atherosclerosis is to administer apoA-I. The isolated injec-
tion of apoA-I in rabbits on a cholesterol-rich diet prevented
lesion development, but did not reverse existing lesions [6].
Repeated HDL injection in rabbits on a cholesterol-rich
diet does reduce atherosclerosis and even make it regress
[5]. Short-term effects of intravenous apoA-I injection in hu-
mans have also been described [259]. The possibility of us-
ing apoA-I with mutations which seem to increase the bene-
ficial effect of natural apoA-I, such as apoA-I Milano, also
exists. There is considerable data on animal experimenta-
tion demonstrating the anti-atherogenic and anti-thrombotic
power of apoA-I Milano [21-23], consistent with clinical and
epidemiological data on the population where this mutation
was detected. It is, therefore, plausible to believe that accu-
mulated knowledge on the metabolism of HDL and their rela-
tionship with atherosclerosis, albeit incomplete, holds out a
promise for future therapeutic interventions [260].
Another more conventional therapeutic alternative is
based on the use of drugs to raise HDL cholesterol in plas-
ma. Various clinical-epidemiological studies on patients
treated with lipid-lowering drugs concluded that a 1% incre-
ment in HDL cholesterol concentration corresponded to a
3% reduction in the incidence of myocardial infarctions [2].
This has been demonstrated in secondary prevention of pa-
tients treated with gemfibrozil who showed decreased HDL
cholesterol but normal LDL cholesterol [261]. However, this
and other lipid-lowering treatments decrease plasma triglyc-
erides; thus, in studies of this type with substances which
only affect HDL, whether there is reduction, and to what de-
gree, of atherothombotic cardiovascular events needs to be
examined. One of the few drugs which act specifically by in-
creasing HDL cholesterol is phenytoin, whose effect needs
to be examined further in this type of study, especially in the
course of treatment of patients with isolated hypoal-
phalipoproteinaemia [262]. Our group has treated different
strains of mice susceptible to atherosclerosis with this drug,
and although it does not reduce the area of atherosclerosis
in apoE knock-out mice and LDL-receptor knock-out mice
(Trocho et al., unpublished data), it does improve the
lipoprotein profile and decrease the atherosclerosis suscep-
tibility of control mice, especially females [263], fed a high-
fat diet.
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